Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22444194 | 1.00 | SIGMAR1 (0.42) | SIGMAR1GBA1ACHECYP11B2HTR1A | |
| SCHEMBL22443386 | 0.91 | SPHK2 (0.41) | SIGMAR1GBA1ACHECYP11B2 | |
| SCHEMBL22443385 | 0.91 | SPHK2 (0.41) | SIGMAR1GBA1ACHECYP11B2 | |
| SCHEMBL22443525 | 0.85 | SIGMAR1 (0.45) | SIGMAR1GBA1ACHECYP11B2MEN1 | |
| SCHEMBL17979137 | 0.82 | GBA1 (0.41) | SIGMAR1GBA1ACHEHTR1A | |
| SCHEMBL30753288 | 0.82 | GBA1 (0.41) | SIGMAR1GBA1ACHEHTR1A | |
| SCHEMBL21441827 | 0.82 | GBA1 (0.41) | SIGMAR1GBA1ACHEHTR1A | |
| SCHEMBL22453781 | 0.81 | VEGFA (0.40) | SIGMAR1ACHEMEN1KMT2AGAA | |
| SCHEMBL31538006 | 0.78 | SIGMAR1 (0.49) | SIGMAR1GBA1ACHEMEN1TSHR | |
| SCHEMBL22443656 | 0.78 | GBA1 (0.38) | SIGMAR1GBA1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-06-23 | — | — | US | disclosed |
| EP-3941913-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| CN-113784961-A | Heteroaryl (heterocyclyl) carbinol compounds useful for treating hyperglycemia | 阿托基公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020188299-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | SIGMAR1 2185/4885GBA1 249/4885ACHE 1238/4885 |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | SIGMAR1 2185/4885GBA1 249/4885ACHE 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.